To the full analysis
Pharming Group stock: valuation and P/E
PHARM.ASPharming Group trades at a P/E of 39.4 (Biotechnology median 21.7, own median of recent years 30.1).
Daily figure as of 13 Nov 2026
P/E
39.4
P/S
2.4
P/B
3.36
PEG
3.06
Against its own valuation history
Each fiscal year is shown with its P/E on the year-end date, using the price at the time.
P/E
39.4
Median of prior years
30.1
Reading
pricier than usual
P/E at each fiscal year end
Figures as a table
| Year | P/E |
|---|---|
| 2018 | 21.5 |
| 2019 | 30.1 |
| 2020 | 27.4 |
| 2021 | 34.1 |
| 2022 | 64.5 |
| 2025 | 348.8 |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
- Valuation signal Overvalued since 10 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.